Melatonin as a potential treatment for septic cardiomyopathy
Septic cardiomyopathy (SCM) is a common complication of sepsis contributing to high mortality rates. Its pathophysiology involves complex factors, including inflammatory cytokines, mitochondrial dysfunction, oxidative stress, and immune dysregulation. Despite extensive research, no effective pharmac...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S075333222301096X |
| _version_ | 1797686888496103424 |
|---|---|
| author | Amira Mohamed Taha Abdelrahman Mohamed Mahmoud Mohamed M. Ghonaim Ateeba Kamran Jehad Feras AlSamhori Majd M. AlBarakat Abhigan Babu Shrestha Vikash Jaiswal Russel J. Reiter |
| author_facet | Amira Mohamed Taha Abdelrahman Mohamed Mahmoud Mohamed M. Ghonaim Ateeba Kamran Jehad Feras AlSamhori Majd M. AlBarakat Abhigan Babu Shrestha Vikash Jaiswal Russel J. Reiter |
| author_sort | Amira Mohamed Taha |
| collection | DOAJ |
| description | Septic cardiomyopathy (SCM) is a common complication of sepsis contributing to high mortality rates. Its pathophysiology involves complex factors, including inflammatory cytokines, mitochondrial dysfunction, oxidative stress, and immune dysregulation. Despite extensive research, no effective pharmacological agent has been established for sepsis-induced cardiomyopathy. Melatonin, a hormone with diverse functions in the body, has emerged as a potential agent for SCM through its anti-oxidant, anti-inflammatory, anti-apoptotic, and cardioprotective roles. Through various molecular levels of its mechanism of action, it counterattacks the adverse event of sepsis. Experimental studies have mentioned that melatonin protects against many cardiovascular diseases and exerts preventive effects on SCM. Moreover, melatonin has been investigated in combination with other drugs such as antibiotics, resveratrol, and anti-oxidants showing synergistic effects in reducing inflammation, anti-oxidant, and improving cardiac function. While preclinical studies have demonstrated positive results, clinical trials are required to establish the optimal dosage, route of administration, and treatment duration for melatonin in SCM. Its safety profile, low toxicity, and natural occurrence in the human body provide a favorable basis for its clinical use. This review aims to provide an overview of the current evidence of the use of melatonin in sepsis-induced cardiomyopathy (SICM). Melatonin appears to be promising as a possible treatment for sepsis-induced cardiomyopathy and demands further investigation. |
| first_indexed | 2024-03-12T01:12:09Z |
| format | Article |
| id | doaj.art-c459bd10685344b0b75f7c119a5c02cc |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-12T01:12:09Z |
| publishDate | 2023-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-c459bd10685344b0b75f7c119a5c02cc2023-09-14T04:52:34ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-10-01166115305Melatonin as a potential treatment for septic cardiomyopathyAmira Mohamed Taha0Abdelrahman Mohamed Mahmoud1Mohamed M. Ghonaim2Ateeba Kamran3Jehad Feras AlSamhori4Majd M. AlBarakat5Abhigan Babu Shrestha6Vikash Jaiswal7Russel J. Reiter8Faculty of Medicine, Fayoum University, Fayoum, Egypt; Medical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USAFaculty of Medicine, Menoufia University, Menoufia, EgyptFaculty of Medicine, Menoufia University, Menoufia, EgyptBachelor of Medicine, Bachelor of Surgery, Karachi Medical and Dental College, Karachi, PakistanFaculty of Medicine, University of Jordan, Amman, JordanFaculty of Medicine, Jordan University of Science and Technology, Irbid, JordanDepartment of Internal Medicine, M Abdur Rahim Medical College, Dinajpur, Bangladesh; Correspondence to: M Abdur Rahim Medical College, Dinajpur, Bangladesh.Larkin Community Hospital, South Miami, Fl, USADepartment of Cell Systems and Anatomy, UT Health San Antonio, San Antonio, TX, USASeptic cardiomyopathy (SCM) is a common complication of sepsis contributing to high mortality rates. Its pathophysiology involves complex factors, including inflammatory cytokines, mitochondrial dysfunction, oxidative stress, and immune dysregulation. Despite extensive research, no effective pharmacological agent has been established for sepsis-induced cardiomyopathy. Melatonin, a hormone with diverse functions in the body, has emerged as a potential agent for SCM through its anti-oxidant, anti-inflammatory, anti-apoptotic, and cardioprotective roles. Through various molecular levels of its mechanism of action, it counterattacks the adverse event of sepsis. Experimental studies have mentioned that melatonin protects against many cardiovascular diseases and exerts preventive effects on SCM. Moreover, melatonin has been investigated in combination with other drugs such as antibiotics, resveratrol, and anti-oxidants showing synergistic effects in reducing inflammation, anti-oxidant, and improving cardiac function. While preclinical studies have demonstrated positive results, clinical trials are required to establish the optimal dosage, route of administration, and treatment duration for melatonin in SCM. Its safety profile, low toxicity, and natural occurrence in the human body provide a favorable basis for its clinical use. This review aims to provide an overview of the current evidence of the use of melatonin in sepsis-induced cardiomyopathy (SICM). Melatonin appears to be promising as a possible treatment for sepsis-induced cardiomyopathy and demands further investigation.http://www.sciencedirect.com/science/article/pii/S075333222301096XMelatoninPineal glandSepsisSeptic cardiomyopathy |
| spellingShingle | Amira Mohamed Taha Abdelrahman Mohamed Mahmoud Mohamed M. Ghonaim Ateeba Kamran Jehad Feras AlSamhori Majd M. AlBarakat Abhigan Babu Shrestha Vikash Jaiswal Russel J. Reiter Melatonin as a potential treatment for septic cardiomyopathy Biomedicine & Pharmacotherapy Melatonin Pineal gland Sepsis Septic cardiomyopathy |
| title | Melatonin as a potential treatment for septic cardiomyopathy |
| title_full | Melatonin as a potential treatment for septic cardiomyopathy |
| title_fullStr | Melatonin as a potential treatment for septic cardiomyopathy |
| title_full_unstemmed | Melatonin as a potential treatment for septic cardiomyopathy |
| title_short | Melatonin as a potential treatment for septic cardiomyopathy |
| title_sort | melatonin as a potential treatment for septic cardiomyopathy |
| topic | Melatonin Pineal gland Sepsis Septic cardiomyopathy |
| url | http://www.sciencedirect.com/science/article/pii/S075333222301096X |
| work_keys_str_mv | AT amiramohamedtaha melatoninasapotentialtreatmentforsepticcardiomyopathy AT abdelrahmanmohamedmahmoud melatoninasapotentialtreatmentforsepticcardiomyopathy AT mohamedmghonaim melatoninasapotentialtreatmentforsepticcardiomyopathy AT ateebakamran melatoninasapotentialtreatmentforsepticcardiomyopathy AT jehadferasalsamhori melatoninasapotentialtreatmentforsepticcardiomyopathy AT majdmalbarakat melatoninasapotentialtreatmentforsepticcardiomyopathy AT abhiganbabushrestha melatoninasapotentialtreatmentforsepticcardiomyopathy AT vikashjaiswal melatoninasapotentialtreatmentforsepticcardiomyopathy AT russeljreiter melatoninasapotentialtreatmentforsepticcardiomyopathy |